natgillin/translations-raw huggingface dataset:
Thus the invention provides the use of a combination of testosterone or an analogue thereof and tadalafil, in the preparation of a medicament for the treatment of female sexual dysfunction, wherein said testosterone or an analogue thereof and tadalafil are released at essentially the same time and wherein said testosterone or an analogue thereof is provided such that there is a peak of testosterone or an analogue thereof in the blood circulation of the subject to whom it is administered. 
Uporaba kombinacije testosterona ili njegovog analoga koji ima istu vrstu aktivnosti, i tadalafila, u preparaciji medikamenta za liječenje seksualne disfunkcije kod žena, naznačena time što se tadalafil oslobađa u isto vrijeme kada i navedeni testosteron ili njegov analog, i gdje su navedeni testosteron ili njegov analog pruženi u vidu sublingvalne, buko-mukozne ili intranazalne formulacije, tako da se pik nivoa testosterona u serumu dobiva 1-20 minuta nakon primjene, pa se pikovi efekta testosterona ili njegovog analoga i tadalafila preklapaju.
a cyclic peptide formable or formed by the amino acid sequence as depicted in any one of SEQ ID NO: 41, 43, 1 to 4 and 17 to 20; 
Ciklički peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što ima aminokiselinski slijed Asp-Glu-Ala-Arg-Arg-Cys-Tyr-Asn-Asp-Pro-Lys; ili Glu-Ser-Asp-Glu-Ala-Arg-Arg-Cys-Tyr-Asn-Asp-Pro-Lys.
In most embodiments of the methods of the invention, the final concentration of the chaotrope is from about 0.1 molar (0.1 M) to about 2 M, the kosmotrope is from about 0.1 M to about 2 M, the chelator is from about 0.1 M to about 2 M, and the apoptosis substrate is from about 0.001 M to about 0.5 M in the reagent for tissue samples. 
Reagens prema zahtjevu 1, naznačen time da konačna koncentracija barem jednog kaotropa je od 0.1 Molarno do 2 Molarno, konačna koncentracija barem jednog kozmotropa je od 0.1 Molamo do 2 Molarno, konačna koncentracija kelatora je od 0.1 M do 2 Molarno, i konačna koncentracija supstrata apoptoze je od 0.001 Molarno do 0.5 Molarno.
An oat-based B-glucan concentrate, characterized in that its B-glucan content is 30 to 40%, and it is composed of B-glucan of the oat aleurone, protein content is 22 to 35%, starch content is at most 15%, preferably at most 10%, fat content is less than 3.5%, preferably less than 2%, volume-average particle size is 160 to 280 µm, and at least 95% of the particles are between 35 and 1,000 µm, and that it is obtained from step (c) of the method of claim 1. 
Koncentrat B-glukana na bazi zobi, naznačen time što sadržaj B-glukana je 30 do 40%, 1 sastoji se od B-glukana 1z aleurona zobi, sadržaj proteina je 22 do 35%, sadržaj škroba je najviše 15%, poželjno najviše 10%, sadržaj masti je manji od 3.5%, poželjno manji od 2%, volumno-prosječna veličina čestica je 160 do 280 um, i barem 95% čestica je između 35 1 1,000 um, i dobiva se iz koraka (c) postupka prema zahtjevu 1.
25-60 wt.% of a structuring fat selected from the group consisting of palm oil, palm oil fractions, lauric fat, lauric fat fractions, fully hydrogenated vegetable oil, and combinations thereof; wherein the red palm oil contains at least 200 ppm of carotenoids and 200 ppm of tocotrienols. 
- 25-60%, težinski, strukturne masti, koju se bira iz skupine koju čine palmino ulje, frakcije palminog ulja, laurinska mast, frakcije laurinske masti, posve hidrogenirano biljno ulje, i njihove kombinacije; gdje ulje crvene palme sadrži najmanje 200 ppm karotenoida i 200 ppm tokotrienola.
with a compound of Formula Ib 
Formula la sa spojem Formule Ib
The method of claim 1, wherein the receptor that binds the antigen comprises a recombinant antigen receptor. 
T-stanica koja sadrži: rekombinantni receptor antigena, koji veže antigen; i vektor koji kodira ko-stimulacijski ligand, navedeni ko-stimulacijski ligand je CD80 ili 4-IBBL.
or N—oxide, addition salt, or quaternary amine thereof. 
HR P20160533 T1 ili N-oksid, adicijska sol, kvaterni amin, ili njihov metalni kompleks.
The SGLT2 inhibitor of formula I will be employed in a weight ratio to the meglitinide, PPAR-gamma agonist, PPAR-alpha/gamma dual agonist, aP2 inhibitor or DPP4 inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.2:1 to about 10:1. 
SGLT2 inhibitor formule I će se koristiti u odnosu masa prema meglitinidu, PPAR-gama agonistu, PPAR-alfa/gama dvostrukom agonistu, aP2 inhibitoru ili DPP4 inhibitoru unutar opsega od oko 0.01:1 do oko 100:1, poželjno od oko 0.2:1 do oko 10:1.
The expandable sheath of claim 1, wherein the inner member comprises at least one notch extending proximally from a distal end of the inner member. 
Navlaka (8) prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što nadalje sadrži najmanje jednu uzdužnu šipku (60) spojenu na unutarnju površinu unutarnjeg cjevastog sloja (42).
This leads to so-called “thymine-less death” in cancer cells. 
Ovo vodi do takozvane "smrt uslijed nedostataka timina " u stanicama raka.
Fermentation of polydextrose also leads to the growth of favourable microflora, diminished putrefactive microflora and enhanced production of short chain fatty acids. 
Fermentacijom polidekstroze pospješuje se 1 rast poželjne mikroflore, smanjuje putrefakcijska mikroflora 1 potiče proizvodnja kratkolančanih masnih kiselina.
The compound for use in a method of treating a Plasmodium related disease according to claim 10, wherein the compound is administered prior to, simultaneously with, or after the second agent. 
Spoj za uporabu u liječenju bolesti koja se odnosi na plazmodij prema zahtjevu 7, ili uporaba prema zahtjevu 11, naznačen(a) time, da se prilikom liječenja, spoj daje prije, istovremeno ili nakon drugog sredstva.
1, 2, 16, and 21 for the manufacture of a medicament for treating depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa or premenstrual tension. 
. Uporaba spoja u skladu s bilo kojim zahtjevom 1 do 11, naznačena time, da se koristi za izradu lijeka za liječenje depresije, atipične depresije, bipolarnog poremećaja, anksioznosti, opsesivno-kompulsivnog poremećaja, socijalne fobije ili stanja paniko, poremećaja spavanja, seksualne disfunkcije, psihoza, šizofrenije, migrene ili stanja povezanih sa glavoboljom ili ostalom boli, povećanog intakranijalnog tlaka, epilepsije, poremećaja osobnosti, poremećaja ponašanja povezanih ga dobi, poremećaja ponašanja povezanih sa demencijom, organskog mentalnog poremećaja, mentalnog poremećaja u djetinjstvu, agresivnosti, poremećaja pamćenja povezanih s dobi, sindroma
This effect is particularly important in preventing osteoporosis. 
Taj je učinak važan prvenstveno za sprječavanje osteoporoze.
The DRX spectra of the crystalline form present in the cream are indicated in Fig. 28 . A process for preparing cortexolone-17a-propionate in crystalline form I, wherein said crystalline form I is characterized by a DRX spectrum as represented in Figure 1 and by a DSC spectrum as represented in Figure 2 and by an IR spectrum as represented in Figure 3, said process comprising reacting a compound of Formula II: with a compound of Formula III R'OH (III) in the presence of a lipase from Candida, wherein R is CH3-CH2, and R' is a linear aliphatic chain containing 1-10 carbon atoms to give cortexolone-17a-propionate, and crystallizing said cortexolone-17a-propionate from tert-butylmethylether, to give cortexolone-17a-propionate in crystalline form I. 
PATENTNI ZAHTJEVI M» Farmaceutski pripravak koji sadrži najmanje jedan kristalni oblik korteksolon-17a-propionata u vezi sa najmanje jednim fiziološki prihvatljivim ekscipijensom, gdje navedeni najmanje jedan kristalni oblik korteksolon-17a- propionata je odabran od: kristalnog oblika I okarakterizirano pomoću DRX kao što je prikazano na slici 11 DSC kao što je prikazano na slici 2 i IR spektra kao što je prikazano na slici 3; kristalnog oblika III okarakterizirano pomoću DRX spektra kao što je prikazano na slici 7 ili 10 ili 13 1 DSC spektra kao što je prikazano na slici 8 ili 11 ili 141 IR spektra kao što je prikazano na slici 9 ili 12 ili 15; hidratnog kristalnog oblika IV okarakterizirano pomoću DRX spektra kao što je prikazano na slici 28.
IL-2 microaggregates were prepared as described above, with a SDS concentration of 160µg/mg, and were analysed by DLS. 
Mikroagregati IL-2 pripravljeni su kako je gore opisano uz koncentraciju SDS od 160ug/mg i analizirani su pomoću DLS.
The term "heteroarylalkyl" as used herein alone or as part of another group refers to alkyl groups as defined above having a heteroaryl substituent, wherein said heteroaryl and/or alkyl groups may optionally be substituted as defined above. 
Termin "heteroarilalkil" kao što se ovdje upotrebljava samostalno ili kao dio druge skupine odnosi se na alkilnu skupinu kao što je gore definirano koja ima heteroarilni supstituent, gdje spomenuta heteroaril i/ili alkilna skupina može biti opcijski supstituirana kao što je gore definirano. i slično.
The name of documents are shown in the column of available manufacturer, meaning that the compound is formed in accordance with the method described in the document. 
Spoj ili njegova sol ili solvat u skladu s patentnim zahtjevom 1, naznačen time, daje spoj odabran iz sljedećih skupina koje se sastoje od
A polypeptide whose amino acid sequence comprises or consists of one of the following sequences: 
HR P20140886 T1 PATENTNI ZAHTJEVI Polipeptid čija aminokiselinska sekvenca obuhvaća ili se sastoji od jedne od sljedećih sekvenci:
The process for preparing a vaccine composition as claimed in claim 17, wherein the conjugate obtained in a) is combined with diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens toxoid and filamentous hemagglutinin. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, i 2 acelularna antigena Bordetella pertussis, koji su toksoid i filamentozni hemaglutinin.
The mixture was evaporated and the residue dissolved in ethanol (500ml) and palladium on carbon (4.0g) and acetic acid (10ml) added and the reaction mixture was stirred under an atmosphere of hydrogen for 3 hours. 
Smjesu se otpari, ostatak otopi u etanolu (500 ml), te se doda paladij na ugljiku (4,0 g) i octena kiselina (10 ml), a reakcijsku smjesu miješa 3 sata u atmosferi vodika.
selecting an antibody producing cell which produces the antibody which binds to human ILT7 from the antibody producing cell of the immune animal; and 
(2) odabir jedne stanice, koja proizvodi antitijelo koje se veže na humani ILTY7, iz stanice imune životinje koja proizvodi to antitijelo.
an alkyl, cycloalkyl, aryl, heretoaryl group comprising either at least one nitrogen or oxygen heteroatom or which group is substituted by at least one amino group or oxo group; 
alkilne, cikloalkilne, arilne, heteroarilne skupine koja se sastoji od najmanje jednog heteroatoma dušika ili kisika ili je supstituirana najmanje jednom aminskom ili okso-skupinom
The method of claim 1, wherein the trafficking sequence domain consists of the amino acid sequence of SEQ ID NO: 5, 6, 7, 8, 21 or 22. 
Kimerni peptid za uporabu prema bilo kojem zahtjevu 1 do 4, naznačen time da se transportna sekvenca sastoji od ili sadrži sekvencu amino kiseline sa SEQ ID NO: 5, 6, 7,8, 21 ili 22.
The reactor (3; 3 ′) as claimed in claim 9 wherein the heating means is resistor heater, air fan heating, infrared heater or microwave heater or combination thereof. 
Reaktor (3, 3'), prema zahtjevu 9, naznačen time da je dio aparature za zagrijavanje može biti grijač s otpornicima, grijač sa zračnim puhačem, infracrveni grijač ili mikrovalni grijač ili kombinacija navedenih grijača.
A suitable design makes it possible for the up-and-down movement of the plunger to be carried out just once, so that it is ensured that fluid is not unintentionally sucked up and then returned to the user's body. 
Prikladna naprava omogućava da se pomicanje klipa gore i dolje obavi samo jednom, tako da se osigura da se fluid nenamjerno ne usiše i tada opet vrati u tijelo korisnice.
The antibiotic agents are usually employed in an amount from 0.1 to 10 wt.%. 
Antibiotski agensi obično se koriste u količini od 0,1 do 10 težinskih %.
A transgenic plant cell obtained according to the method of any of embodiments 74 or 75. 
Transgenska biljna stanica ili transgenska biljka, naznačena time, da se dobiva u skladu s postupkom prema zahtjevu 10ili 11.
a further therapeutic agent; or 
(a) dodatnim terapijskim sredstvom; ili
The mixture was stirred at room temperature for 4 hours. 
Smjesa je mješana pri sobnoj temepraturi 4 sata.
Three grooves 5, 6, 7 have been formed in the circumferential surface 2, which are longitudinally extending over the total length of the post 1 and twisted along the circumference of the surface 2 . 
Zubni most u skladu s patentnim zahtjevom 1, naznačen time što se navedeni ušiljeni dio pruža preko najmanje jedne trećine ukupne duljine navedenog mosta.
Preferred materials are those which are selected from the group consisting of alkylcelluloses, hydroxyalkylcelluloses, glucans, scleroglucans, mannans, xanthans, copolymers of poly[bis(p-carboxyphenoxy)propane and sebacic acid, preferably in a molar ratio of 20:80 (commercially available under the name Polifeprosan 20®), carboxymethylcelluloses, cellulose ethers, cellulose esters, nitrocelluloses, polymers based on (meth)acrylic acid and the esters thereof, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, halogenated polyvinyls, polyglycolides, polysiloxanes and polyurethanes and the copolymers thereof. 
Pogodni materijali su takvi, koji su izabrani iz skupine koja obuhvaća alkilceluloze, hidroksialkilceluloze, glukane, skleroglukane, manane, ksantane, kopolimere iz poli[bis(p-karboksifenoksi) propana i sebacinske kiseline, prvenstveno u molnom odnosu od 20:80 (koji se na tržištu vodi pod oznakom Polifeprosan 20%), karboksimetilceluloze, celulozne etere, celulozne estere, nitroceluloze, polimere na bazi (met)akrilne kiseline, kao i njezine estere, poliamide, polikarbonate, polialkilene, polialkilenglikole, polialkilenokside, polialkilentereftalate, polivinilalkohole, poliviniletere, polivinilestere, halogenirane polivinile, poliglikolide, poliosiloksane, kao i poliuretane i polimere ovih.
and R2, are both —OR8, or R1 and R2, together with the carbon atom to which they are attached, form dioxacycloalkyl; 
(i) R'iR su oba -OR*, ili R' i R", zajedno s atomom ugljika na kojeg su vezani, tvore dioksacikloalkil;
Four fresh pineapples that had no coating were used as controls and four pineapples and crowns of the fruit were coated with a 5% emulsion as in example 1. 
Četiri svježa ananasa bez ovojnice korišteni su kao kontrole i četiri ananasa i krune voća obloženi su sa 5% emulzijom kao u primjeru 1.
a compensation unit (120) arranged to retrieve, from the storage unit, information matching a type of data symbol of a transmission signal from among the stored information, and insert a Peak Reduction Kernel signal for reducing a Peak to Average Power ratio, PAPR, based on the retrieved information into the transmission signal, 
primanje prijenosnog signala, preuzimanje, iz memorije, pozicijskih informacija koje odgovaraju vrsti simbola podataka prijenosnog signala između pohranjenih pozicijskih informacija, i oporavak podatkovnog simbola iz prijenosnog signala temeljem dohvaćenih podataka o položaju.
The device according to claim 1, wherein the working bodies (7) are in the shape of a barrel or a sphere and are either solid or hollow. 
što su radna tijela (7) izvedena od punog ili šupljeg materijala, a prvenstveno u obliku bačve ili kugle.
The present invention employs analogous chemistry, but with the difference that this reaction is performed after that the coating formulation has been applied as a thin film on a substrate. 
Predloženi izum koristi analognu kemiju, ali s tom razlikom da se ta reakcija provodi nakon nanošenja formulacije premaza u obliku tankog filma na podlogu.
The process of claim 11 further comprising coupling an amino-terminal protected Asp having a protected carboxyl side chain to a Trp-Pro dipeptide through the Trp of the dipeptide and removing the amino-terminal protecting group from the Asp to form the 4-6 eptifibatide sequence. 
Produkt prema patentnom zahtjevu 10, naznačen time da navedeni postupak nadalje sadrži vezanje zaštićenog amino-terminalnog rezidua Asp koji ima zaštićeni karboksilni bočni lanac na Trp-Pro dipeptid putem rezidua Trp dipeptida i uklanjanje zaštitne amino- terminalne skupine iz rezidua Asp kako bi se formirao fragment 4-6 eptifibatida.
The information system according to any of the preceding claims wherein the absorber is provided at a distance larger than 0, preferably between 0.1 to 50 mm, more preferably between 0.2 to 10 mm, and most preferably between 0.5 and 2.5 mm from the reflector (12, 13). 
Informacijski sustav u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje je prigušivač osiguran na udaljenosti većoj od 0, poželjno između 0.1 do 50 mm, poželjnije između 0.2 do 10 mm, i najpoželjnije između 0.5 i 2.5 mm od reflektora (12, 13).
This has the same external diameter as cylinder 34. 
Ovaj ima iste vanjske dimenzije kao 1 cilindar 34.
treatement of squamouse degeneration of macula in eyes; 
- liječenje skvamozne degeneracije makule u oku;
In one embodiment of the invention, the reaction according to step a) above can be carried out by hydrolyzing a compound of Formula II to the corresponding acid in the presence of NaOH in an aqueous alcohol, such as aqueous methanol or ethanol, at reflux for 1 to 3 hours. 
15 U jednoj izvedi ovoga izuma, reakcija sukladna koraku a) može se provoditi hidroliziranjem spoja s formulom II do odgovarajuće kiseline u prisutnosti NaOH u vodenom alkoholu, poput vodenog metanola ili etanola, u uvjetima refluksa tijekom 1 do 3 h.
This material was used without further purification. 
Taj se materijal koristi bez daljnjeg pročišćavanja.
A compound of formula (I): or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: 
Spoj sukladno zahtjevu 1, s formulom: (JA ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
During the middle stage, patients become more disabled and typically need assistance with some of their routine daily activities. 
Za vrijeme srednjeg stadija, pacijent postaje više nemoćan i uobičajeno treba pomoć u svojim rutinskim, dnevnim aktivnostima.
selecting at least one cell-line which produces a heavy chain-only antibody which binds specifically to the antigen. 
(6) odabir barem jedne stanične linije koja proizvodi antitijelo koje sadrži samo teški lanac koje se specifično veže na antigen, pri čemu je sisavac miš ili štakor.
A cementitious binder according to claim 1 or 2, in which the superplasticiser is a polycarboxylate-ether-based (PCE) superplasticiser. 
Cementno vezivo prema zahtjevu 1 ili 2, naznačeno time što superplastifikator je superplastifikator na bazi polikarboksilat-etera (PCE).
The method of claim 7, wherein the viscous slurry is solidified to a firm hydrogel by a pH or temperature change or by cross linking before the snap freezing. 
Postupak pripreme sukladno patentnom zahtjevu 7, naznačen time da se suspenzija stegne u čvrst hidrogel promjenom pH ili temperature ili križnim povezivanjem polimernih lanaca prije trenutnog zamrzavanja.
The method of claim 16, wherein the concentration of pharmaceutical substance in the blood is approximately constant or essentially constant for about 3 months to about 24 months. 
Farmaceutska tvar za primjenu prema patentnom zahtjevu 10, naznačena time, što je brzina oslobađanja farmaceutske tvari u krv otprilike konstantna ili u suštini konstantna tijekom najmanje 3 mjeseca, 6 mjeseci, 12 mjeseci, 15 mjeseci, 18 mjeseci, 21 mjesec ili 24 mjeseca.
a positive signal in a SNP assay using a SNP-probe comprising the nucleotide sequence described by SEQ ID NO: 12 and a negative signal using a SNP-probe comprising the nucleotide sequence described by SEQ ID NO: 11, 
pozitivni signal u SNP testu korištenjem SNP-sonde koja sadrži nukleotidnu sekvencu opisanu sa SEQ ID NO: 12 i negativni signal korištenjem SNP-sonde koja sadrži nukleotidnu sekvencu opisanu sa SEQ ID NO: 11, i
An antifoaming agent is recommended when the coating is being applied to post harvest produce commercially. 
Sredstvo protiv stvaranja pjene se preporučuje kada se ovojnica primjenjuje na ubrani proizvod komercijalno.
The ABM or antibody of item 24, wherein at least about 20% to about 100% of the N-linked oligosaccharides in the Fc region are bisected. 
Protutijelo u skladu sa zahtjevom 7, naznačeno time, da su najmanje 20% do 100% N-vezanih oligosaharida u Fc regiji nefukozilirani.
After the addition was completed, the reaction mixture was stirred for 17 hours at room temperature under nitrogen and then filtered. 
Postoje dodavanje završeno, reakcijska smjesa se miješa 17 sati na sobnoj temperaturi pod dušikom i tada se filtrira.
A third aspect of the present invention is directed to the use of a solid support recycled according to a method of the present invention for cultivation of cells. 
Također je ovdje razotkrivena i uporaba krute potpore za uzgoj stanica koja se reciklira sukladno postupku iz ovoga izuma.
A refrigeration system comprising a condenser and an evaporator, wherein the evaporator temperature of the refrigeration system is below 0°C (32°F), and wherein the refrigeration system contains a refrigerant composition as defined in claim 1. 
Sustav prema zahtjevu 12, naznačen time da je rashladna tvar kako je definirana u zahtjevu 3, te pri čemu je sustav hladnjak koji radi na temperaturi od -17.8"C (0%F).
detecting growth or inhibition of growth of the microorganism with the indicator; 
detektiranje rasta ili inhibicije rasta mikroorganizma pomoću indikatora;
wherein in step (d) the weight ratio of fibres to filler on a dry weight basis is from 1:33 to 10:1, wherein the Brookfield viscosity of the nano-fibrillar cellulose gel formed in step (d) is lower than the Brookfield viscosity of a corresponding nano-fibrillar cellulose suspension having been fibrillated in the absence of the filler. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je viskoznost dobivenog gela od nanofibrilarne celuloze prema Brookfieldu manja od viskoznosti odgovarajuće suspenzije nanofibrilarne celuloze prema Brookfieldu jer je fibrilirana u odsutnosti punila i/ili pigmenata.
An assembly for implanting a balloon-expandable prosthetic aortic heart valve in a patient's body, comprising: 
Sklop za ugradnju protetskog aortnog ventila (10) sa proširivim balonom u tijelo pacijenta, pri čemu sklop obuhvaća:
A 2-methyl tetrahyrdrofuran solvate of Compound (1), wherein Compound (1) is represented by the following structural formula: 
Polimorfni oblik Spoja (1) u skladu s patentnim zahtjevom 1, kojeg prikazuje sljedeća strukturna formula FK Nr \ |
Packaging system for pharmaceutical compositions and kit for intravenous administration 
SUSTAV PAKIRANJA FARMACEUTSKIH SASTAVA I KOMPLET ZA INTRAVENOZNO DAVANJE
An apparatus according to claim 1, wherein said single push-pull-turn hose (5) is in fluidic connection with the interior of the bladder (110) via a conduit (25) in the proximal collar fitting (3). 
Uređaj prema bilo kojem od zahtjeva od 1 do 3, naznačen time da je spomenuto crijevo za potiskivanjepovlačenje-okretanje (5) protočno povezano s unutrašnjosti mjehura koji se napuhuje (110) preko voda (25) u proksimalnoj spojnici (3).